

ASX Announcement | 28 September 2020  
Visioneering Technologies (ASX: VTI)

## Positive Five-Year Data Presented at Global Myopia Symposium Shows Long-Term Benefit in Children Wearing VTI's Contact Lenses

### Highlights

- Data from 153 children being treated in 13 optometry practices in the United States for up to 5 years
- On average, children wearing NaturalVue MF experienced a 90% reduction in the worsening of their nearsightedness between 6 months and 5 years
- 93% of children experienced a slowing of their progression in nearsightedness, with 65% experiencing a slowing of greater than 70%
- Annual lengthening of the children's eyes was reduced to normal levels
- No adverse events related to the contact lenses have been reported to the Company

**Atlanta, Georgia, Monday 28 September 2020:** US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering' or 'The Company') has presented positive data at the 25-26 September Global Myopia Symposium (GMS).

### Myopia is a global issue

Pediatric Myopia, or nearsightedness in children, has undergone explosive growth on a global scale over the past four decades and has become a major worldwide eye health issue, with 80-90% of children in many Asian countries being nearsighted, along with high percentages of children in other industrialized nations. Eyecare experts generally believe that minimizing the progression of nearsightedness is an important intervention aimed at minimizing lifetime risks of blindness and other serious ocular diseases that are correlated to nearsightedness.

### Updated data set and timeline build upon previous peer-reviewed results

This new data adds to previously released data sets in that it increases the number of children and optometry practices contributing to the data set, adds longer time points, and includes more extensive data related to the lengthening of the eyes of the children (excessive lengthening of the eye is the cause of nearsightedness). The data shows that even after 5 years, NaturalVue Multifocal contact lenses continue to blunt the progression of nearsightedness in children who are wearing the lenses, and over 3 years of study, substantially slows the lengthening of the children's eyes, or the eye's "axial length."

The updated data include 153 children (mean age 12.0 years) being followed for 6 to 59 months. The data were consistent at each time point, demonstrating approximately 90% decrease (approximately 1.00 Diopters, D) in myopic progression, as compared to the rate of progression prior to wearing NaturalVue Multifocal contact lenses. All timepoints were statistically significantly different from baseline ( $p < 0.00001$ ). Within a subset of 36 children, axial length was measured over time. Axial length change from baseline averaged  $0.11 \pm 0.14$  mm at 12-17M (88% reduction in axial length change as compared to baseline),  $0.20 \pm 0.20$  (66% reduction) at 18-24M, and  $0.17 \pm 0.21$  (55%

reduction) at 30-35M. The Company received no reports of adverse events related to the contact lenses.

**Meaningful probability of clinical effect**

In order to provide data to practitioners and families on the probability of successful treatment with NaturalVue Multifocal contact lenses in the most at-risk patients, a subset analysis of 8-12 year olds was performed for Number Needed to Treat (NNT). NNT is the number of eyes a practitioner would need to treat in order to see an effect deemed clinically significant. This data suggests for every one eye treated, one eye will show the benefit (no meaningful myopic progression over a 3-year period), amounting to meaningful probability of clinical effect.

Each practitioner should come to their own conclusions about how to interpret clinical data and how the data should impact or influence his/her decisions with patients. Further research is needed to understand the clinical importance of these data and how the observations relate to long-term outcomes.

Visioneering CEO Stephen Snowdy, Ph.D., said: “Pediatric myopia is not just an inconvenience; it is a condition that results in higher risk of serious ocular disease over one’s lifetime, and VTI and the practitioners who contributed this data are intensely committed to fighting pediatric myopia. The prevalence and severity of myopia have been increasing at a rapid rate in nearly all industrialized nations, with some Asian nations having 80-90 or more percent of their children affected by myopia. The long-term effectiveness shown by this new data set for NaturalVue Multifocal is very encouraging, especially when combined with the excellent vision experienced by children wearing the lenses. Our goal is to expand the availability of NaturalVue Multifocal globally and to minimize the amount of myopia progression in as many children as possible.”

**Ends.**

**This release was authorized by the CEO, Stephen Snowdy, PhD.**

**For more information, please contact:**

<i><b>Company</b></i>	<i><b>Investor and media relations</b></i>
Stephen Snowdy, PhD CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Julia Maguire The Capital Network M: +61 419 815 386 E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a>

**About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the

United States, Canada, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

### **Foreign ownership restrictions**

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX38